The case for including bowel urgency in toxicity reporting after pelvic cancer treatment.
AuthorsHenson, Caroline C
Anandadas, Carmel N
Barraclough, Lisa H
West, Catharine M L
Davidson, Susan E
AffiliationFrom the Departments of Radiotherapy Related Research, Clinical Oncology, and Statistics, The Christie NHS Foundation Trust, Manchester, United Kingdom.
MetadataShow full item record
AbstractBowel toxicity is a major complication of cancer treatment, and its accurate reporting is important for assessing outcomes. The NCI's Common Terminology Criteria for Adverse Events (CTCAE) is the preferred method for capturing adverse events after all cancer treatments, particularly within clinical trials. However, the CTCAE version 4 does not include urgency of defecation as an item, despite this being one of the most common and persistent adverse consequences of treatment of pelvic cancers. The importance of bowel urgency to patients is well documented, and this treatment effect has a negative impact on social function and quality of life. Bowel urgency is also important clinically because it may represent significant underlying problems. This article presents the case for including patient reported assessment of bowel urgency as an independent item in cancer treatment adverse event reporting.
CitationThe case for including bowel urgency in toxicity reporting after pelvic cancer treatment. 2013, 11 (7):827-33 J Natl Compr Canc Netw
JournalJournal of the National Comprehensive Cancer Network
- Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
- Authors: Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E, National Cancer Institute PRO-CTCAE Study Group.
- Issue date: 2015 Nov
- Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
- Authors: Bruner DW, Hanisch LJ, Reeve BB, Trotti AM, Schrag D, Sit L, Mendoza TR, Minasian L, O'Mara A, Denicoff AM, Rowland JH, Montello M, Geoghegan C, Abernethy AP, Clauser SB, Castro K, Mitchell SA, Burke L, Trentacosti AM, Basch EM
- Issue date: 2011 Mar
- Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
- Authors: Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D
- Issue date: 2014 Sep
- Patient assessment of bowel function during and after pelvic radiotherapy: results of a prospective phase III North Central Cancer Treatment Group clinical trial.
- Authors: Haddock MG, Sloan JA, Bollinger JW, Soori G, Steen PD, Martenson JA, North Central Cancer Treatment Group.
- Issue date: 2007 Apr 1
- Assessment of treatment-induced female sexual morbidity in oncology: is this a part of routine medical follow-up after radical pelvic radiotherapy?
- Authors: White ID, Allan H, Faithfull S
- Issue date: 2011 Sep 27